List view / Grid view
Targeted protein degradation (TPD) is a cutting-edge approach in drug discovery that offers a more precise and efficient way to alter cellular pathways, offering the capability to convert 'undruggable targets' into 'druggable targets.' In this article, Drug Target Review’s Izzy Wood interviewed Astellas’ Masahiko Hayakawa, Head of Targeted Protein Degradation,…
Japanese researchers have designed a pure capped mRNA vaccine which has shown a better protein production in the immune system.
Drug Target Review's Ria Kakkad spoke with Victoria Goldenshtein at PEGs Europe, about her lab’s novel in vitro library display platform for directed protein evolution called GRIP display – gluing RNA to its proteins.
South Korean researchers have developed a hydrogel using a uterus-derived decellularised extracellular matrix, bringing hope for those challenged with infertility.
In this article, learn about how TMEM175 is an exciting new target in normal physiology and in disease. Also, read about how the use of biomarkers in Alzheimer’s drug development will address many of the challenges currently encountered.
Spanish researchers looking at two crucial proteins uncover how cells release mucin and insulin, leading to new methods to reset deregulation.
Here we explore using a mucin-selective protease for tryptic-digest sample preparation of two mucin proteins and assess its potential to improve detecting glycoforms and glycopeptides.
The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stability information to develop successful biologics.
Researchers from Australia explore how viruses can alter brain cells, and thus the functions of our nervous system, leading to neurological symptoms.
Fresh insights from University of Edinburgh into a protein that causes damage in kidneys and hearts could open up new treatment options for chronic kidney disease.
In this infographic, we discuss both inhibition and degradation, the advantages and challenges related to each approach and the key points you need to consider when designing your protein degraders.
US researchers have uncovered a potential target for treating breast cancer that is resistant to endocrine therapies because of a specific gene mutation.
Japanese researchers identify a protein that reduces inflammation, stimulates neural growth, and improves sensory and motor functions following ischemic stroke in mice.
Single-cell transcriptomic RNA sequencing analysis has allowed US researchers to identify the specific populations and the dynamic transition states during senescence initiation and progression.
Chinese researchers use a glycosidic-bond-based mass-spectrometry-cleavable cross-linker to analyse proteins in vivo.
